RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Guangdi Wang to Neoplasms

This is a "connection" page, showing publications Guangdi Wang has written about Neoplasms.
Connection Strength

1.208
  1. Wang G. Cancer Immunotherapy and Immunomodulation. Curr Med Chem. 2019; 26(17):2988-2989.
    View in: PubMed
    Score: 0.342
  2. Zheng S, Liu J, Wu Y, Huang TL, Wang G. Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics. Future Med Chem. 2015; 7(18):2485-505.
    View in: PubMed
    Score: 0.277
  3. Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015 Mar 02; 20(3):3898-941.
    View in: PubMed
    Score: 0.262
  4. Guo S, Zou J, Wang G. Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des Devel Ther. 2013; 7:1259-71.
    View in: PubMed
    Score: 0.238
  5. Komati R, Spadoni D, Zheng S, Sridhar J, Riley KE, Wang G. Ligands of Therapeutic Utility for the Liver X Receptors. Molecules. 2017 Jan 05; 22(1).
    View in: PubMed
    Score: 0.074
  6. Samaan N, Zhong Q, Fernandez J, Chen G, Hussain AM, Zheng S, Wang G, Chen QH. Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents. Eur J Med Chem. 2014 Mar 21; 75:123-31.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support